Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly diagnosed...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Blood cancer journal (New York) Ročník 13; číslo 1; s. 112 - 8
Hlavní autoři:	Tan, Carlyn Rose, Derkach, Andriy, Nemirovsky, David, Ciardiello, Amanda, Diamond, Benjamin, Hultcrantz, Malin, Hassoun, Hani, Mailankody, Sham, Shah, Urvi, Maclachlan, Kylee, Patel, Dhwani, Lahoud, Oscar B., Landau, Heather J., Chung, David J., Shah, Gunjan L., Scordo, Michael, Giralt, Sergio A., Lesokhin, Alexander, Usmani, Saad Z., Landgren, Ola, Korde, Neha
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 25.07.2023 Springer Nature B.V Nature Publishing Group
Témata:	692/699/1541/1990/804 692/700/565/1436/1437 Antineoplastic Combined Chemotherapy Protocols - adverse effects Biomedical and Life Sciences Biomedicine Bortezomib - adverse effects Cancer Research Dexamethasone - therapeutic use Hematology Humans Immunotherapy Induction Chemotherapy Inhibitor drugs Lenalidomide - therapeutic use Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Oncology Retrospective Studies Steroids Targeted cancer therapy
ISSN:	2044-5385, 2044-5385
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!